BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tétreau R, Llacer C, Riou O, Deshayes E. Evaluation of response after SBRT for liver tumors. Rep Pract Oncol Radiother 2017;22:170-5. [PMID: 28490989 DOI: 10.1016/j.rpor.2015.12.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Py JF, Salleron J, Courrech F, Beckendorf V, Croisé-Laurent V, Peiffert D, Vogin G, Dietmann AS. Long-term outcome of Stereotactic Body Radiation Therapy for patient with unresectable liver metastases from colorectal cancer. Cancer Radiother 2021;25:350-7. [PMID: 33618909 DOI: 10.1016/j.canrad.2021.01.004] [Reference Citation Analysis]
2 Nieuwenhuizen S, Dijkstra M, Puijk RS, Timmer FEF, Nota IM, Opperman J, van den Bemd B, Geboers B, Ruarus AH, Schouten EAC, de Vries JJJ, Scheffer HJ, van Geel AM, van Waesberghe JHTM, Swijnenburg RJ, Versteeg KS, Lissenberg-Witte BI, van den Tol MP, Haasbeek CJA, Meijerink MR. Thermal Ablation versus Stereotactic Ablative Body Radiotherapy to Treat Unresectable Colorectal Liver Metastases: A Comparative Analysis from the Prospective Amsterdam CORE Registry. Cancers (Basel) 2021;13:4303. [PMID: 34503113 DOI: 10.3390/cancers13174303] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Vernuccio F, Godfrey D, Meyer M, Williamson HV, Salama JK, Niedzwiecki D, Stephens SJ, Ronald J, Palta M, Marin D. Local Tumor Control and Patient Outcome Using Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: iRECIST as a Potential Substitute for Traditional Criteria. AJR Am J Roentgenol 2019;213:1232-9. [PMID: 31613663 DOI: 10.2214/AJR.18.20842] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Chen ATC, Payão F, Chagas AL, De Souza Melo Alencar RS, Tani CM, da Conceição Vasconcelos KGM, de Souza Rocha M, de Andrade Carvalho H, Hoff PMG, Carrilho FJ. Feasibility of SBRT for hepatocellular carcinoma in Brazil - a prospective pilot study. Rep Pract Oncol Radiother 2021;26:226-36. [PMID: 34211773 DOI: 10.5603/RPOR.a2021.0035] [Reference Citation Analysis]
5 Wang F, Numata K, Takeda A, Ogushi K, Fukuda H, Nihonmatsu H, Hara K, Chuma M, Tsurugai Y, Maeda S. Optimal application of stereotactic body radiotherapy and radiofrequency ablation treatment for different multifocal hepatocellular carcinoma lesions in patients with Barcelona Clinic Liver Cancer stage A4-B1: a pilot study. BMC Cancer 2021;21:1169. [PMID: 34717577 DOI: 10.1186/s12885-021-08897-z] [Reference Citation Analysis]
6 Mazzola R, Fersino S, Alongi P, Di Paola G, Gregucci F, Aiello D, Tebano U, Pasetto S, Ruggieri R, Salgarello M, Alongi F. Stereotactic body radiation therapy for liver oligometastases: predictive factors of local response by 18F-FDG-PET/CT. Br J Radiol 2018;91:20180058. [PMID: 29750538 DOI: 10.1259/bjr.20180058] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
7 Boda-Heggemann J, Jahnke A, Chan MKH, Ghaderi Ardekani LS, Hunold P, Schäfer JP, Huttenlocher S, Wurster S, Rades D, Hildebrandt G, Lohr F, Dunst J, Wenz F, Blanck O. Direct dose correlation of MRI morphologic alterations of healthy liver tissue after robotic liver SBRT. Strahlenther Onkol 2018;194:414-24. [PMID: 29404626 DOI: 10.1007/s00066-018-1271-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
8 Riou O, Azria D, Mornex F. [Stereotactic body radiotherapy for liver tumors: State of the art]. Cancer Radiother 2017;21:563-73. [PMID: 28888744 DOI: 10.1016/j.canrad.2017.07.040] [Cited by in Crossref: 6] [Article Influence: 1.2] [Reference Citation Analysis]
9 Rubio C, Hernando-Requejo O, Zucca Aparicio D, ALlona Krauel M, López Gonzalez M, Pérez JM, Sánchez Saugar E, Fernández Letón P. Image guided SBRT for multiple liver metastases with ExacTrac® Adaptive Gating. Rep Pract Oncol Radiother 2017;22:150-7. [PMID: 28490986 DOI: 10.1016/j.rpor.2016.07.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Mendiratta-lala M, William M, Shampain K, Zhang A, Jo A, Moorman S, Aslam A, Mature K, Davenport M. MRI assessment of hepatocellular carcinoma after local-regional therapy: a comprehensive review. Radiology: Imaging Cancer. 2020;2. [PMID: 33778692 DOI: 10.1148/rycan.2020190024] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
11 Gerum S, Jensen AD, Roeder F. Stereotactic body radiation therapy in patients with hepatocellular carcinoma: A mini-review. World J Gastrointest Oncol 2019; 11(5): 367-376 [PMID: 31139307 DOI: 10.4251/wjgo.v11.i5.367] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
12 Gerena M, Molvar C, Masciocchi M, Nandwana S, Sabottke C, Spieler B, Sharma R, Tsai L, Kielar A. LI-RADS treatment response assessment of combination locoregional therapy for HCC. Abdom Radiol (NY) 2021;46:3634-47. [PMID: 34120207 DOI: 10.1007/s00261-021-03165-x] [Reference Citation Analysis]
13 Han S, Liang X, Li T, Yin FF, Cai J. Slice-stacking T2-weighted MRI for fast determination of internal target volume for liver tumor. Quant Imaging Med Surg 2021;11:32-42. [PMID: 33392009 DOI: 10.21037/qims-20-41] [Reference Citation Analysis]